Apollon Wealth Management’s Autolus Therapeutics AUTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.2K Sell
14,003
-16
-0.1% -$31 ﹤0.01% 1613
2026
Q2
$22.4K Buy
14,019
+16
+0.1% +$25 ﹤0.01% 1566
2026
Q1
$19.3K Buy
+14,003
New +$21.3K ﹤0.01% 1389

Other funds holding AUTL

Apollon Wealth Management's AUTL Position: Q3 2026 in Review

Apollon Wealth Management reduced its Autolus Therapeutics (AUTL) stake by 0.11% in Q3 2026, selling an estimated $31 and leaving 14,003 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

Apollon Wealth Management first reported a position in AUTL in Q1 2026 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

  • Apollon Wealth Management held 14,003 shares of Autolus Therapeutics worth $27.2K as of Q3 2026.
  • Apollon Wealth Management sold 16 Autolus Therapeutics shares in Q3 2026, an estimated $31.
  • Autolus Therapeutics made up ﹤0.01% of Apollon Wealth Management's portfolio in Q3 2026, its #1613 holding.
  • Apollon Wealth Management first reported a position in Autolus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.